title: [Zinc sulfate in the treatment of psoriatic arthritis].
abstract: We evaluated oral zinc sulphate as a disease-modifying antirheumatic drug (DMARD) in psoriatic arthritis in a preliminary open uncontrolled trial. Twenty patients with psoriatic arthritis were given oral zinc sulphate three times a day at total dose of 600 mg/die, i.e. 120 mg/die of elemental zinc, for 6 months. The 18 patients who completed the trial showed a significant decrease in the number of swollen (p less than 0.01) and tender (p less than 0.05) joints, Ritchie articular index (p less than 0.01), need for nosteroidal anti-inflammatory drugs (p less than 0.001), erythrocyte sedimentation rate (p less than 0.01), and plasma copper level (p less than 0.001). We suggest that zinc sulphate may be an effective and well-tolerated DMARD in psoriatic arthritis. To more strictly verify these preliminary data, a double-blind placebo controlled study is in progress.
authors.forename: A
authors.initials: A
authors.lastname: Frigo
authors.forename: C
authors.initials: C
authors.lastname: Tambalo
authors.forename: L M
authors.initials: LM
authors.lastname: Bambara
authors.forename: D
authors.initials: D
authors.lastname: Biasi
authors.forename: M
authors.initials: M
authors.lastname: Marrella
authors.forename: R
authors.initials: R
authors.lastname: Milanino
authors.forename: U
authors.initials: U
authors.lastname: Moretti
authors.forename: G
authors.initials: G
authors.lastname: Velo
authors.forename: G
authors.initials: G
authors.lastname: De Sandre
mesh_terms: D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013431:Sulfates / Q000627:therapeutic use*; D015032:Zinc / Q000627:therapeutic use*; D019287:Zinc Sulfate
chemical_list: D013431:Sulfates; D019287:Zinc Sulfate; D015032:Zinc
vernacular_title: Il solfato di zinco nella terapia dell'artrite psoriasica.